Difference between revisions of "Fluoxetine-paroxetine"

From Psychiatrienet
Jump to: navigation, search
Line 8: Line 8:
 
No wash-out period is needed.  
 
No wash-out period is needed.  
 
* '''Day 1:''' start paroxetine the next day in low dosage of 10 mg/day.
 
* '''Day 1:''' start paroxetine the next day in low dosage of 10 mg/day.
* '''Day 21:''' increase dosage of paroxetine to normal, 20 mg/day.
+
* '''Day 14:''' increase dosage of paroxetine to 20 mg/day.
 
| info =  
 
| info =  
 
* Fluoxetine has a very long elimination time; phasing out fluoxetine is therefore not necessary.  
 
* Fluoxetine has a very long elimination time; phasing out fluoxetine is therefore not necessary.  
 
* {{theorSS}}
 
* {{theorSS}}
 +
* Fluoxetine and norfluoxetine inhibit de metabolism of paroxetine via CYP2D6
 
}}
 
}}

Revision as of 15:12, 27 November 2009

Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from fluoxetine to paroxetine.[1] [2]

Nietinrijdenbord.png Stop fluoxetine
  • Gradually reduce dosage of fluoxetine to a maximum of 20 mg/ day, when this dosage is > 20 mg/day.
  • When a dosage of 20 mg/day is reached, stop administration.
Eenrichtingbord.png Start paroxetine

No wash-out period is needed.

  • Day 1: start paroxetine the next day in low dosage of 10 mg/day.
  • Day 14: increase dosage of paroxetine to 20 mg/day.
Infobord.png More information
  • Fluoxetine has a very long elimination time; phasing out fluoxetine is therefore not necessary.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluoxetine and norfluoxetine inhibit de metabolism of paroxetine via CYP2D6
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.